EP1392293A1 - Method for treatment of tumors using nordihydroguaiaretic acid derivatives - Google Patents
Method for treatment of tumors using nordihydroguaiaretic acid derivativesInfo
- Publication number
- EP1392293A1 EP1392293A1 EP02739227A EP02739227A EP1392293A1 EP 1392293 A1 EP1392293 A1 EP 1392293A1 EP 02739227 A EP02739227 A EP 02739227A EP 02739227 A EP02739227 A EP 02739227A EP 1392293 A1 EP1392293 A1 EP 1392293A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- cells
- cell
- ofthe
- tumor
- spl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 90
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical class C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 title claims description 48
- 238000000034 method Methods 0.000 title claims description 42
- 238000011282 treatment Methods 0.000 title description 61
- 108010002687 Survivin Proteins 0.000 claims abstract description 32
- 102000000763 Survivin Human genes 0.000 claims abstract description 31
- 230000006907 apoptotic process Effects 0.000 claims abstract description 15
- 210000004027 cell Anatomy 0.000 claims description 163
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethyl sulfoxide Natural products CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 99
- 150000001875 compounds Chemical class 0.000 claims description 21
- 238000004519 manufacturing process Methods 0.000 claims description 17
- HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 claims description 16
- 229960003951 masoprocol Drugs 0.000 claims description 16
- 230000022131 cell cycle Effects 0.000 claims description 11
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 210000004962 mammalian cell Anatomy 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 4
- 125000000539 amino acid group Chemical group 0.000 claims description 4
- 210000005260 human cell Anatomy 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 210000004102 animal cell Anatomy 0.000 claims description 3
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 3
- 230000004936 stimulating effect Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 208000003200 Adenoma Diseases 0.000 claims 1
- 206010001233 Adenoma benign Diseases 0.000 claims 1
- 206010043276 Teratoma Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 208000003154 papilloma Diseases 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 39
- 229940079593 drug Drugs 0.000 description 38
- 239000003814 drug Substances 0.000 description 38
- 230000000694 effects Effects 0.000 description 38
- 108090000623 proteins and genes Proteins 0.000 description 33
- 230000014509 gene expression Effects 0.000 description 25
- 230000005764 inhibitory process Effects 0.000 description 25
- 230000001105 regulatory effect Effects 0.000 description 23
- 101000868333 Homo sapiens Cyclin-dependent kinase 1 Proteins 0.000 description 21
- 241000699666 Mus <mouse, genus> Species 0.000 description 21
- 230000027455 binding Effects 0.000 description 20
- 238000002347 injection Methods 0.000 description 20
- 239000007924 injection Substances 0.000 description 20
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- 241000725303 Human immunodeficiency virus Species 0.000 description 18
- 241000701806 Human papillomavirus Species 0.000 description 16
- 230000003902 lesion Effects 0.000 description 16
- 108020004414 DNA Proteins 0.000 description 15
- 102100024829 DNA polymerase delta catalytic subunit Human genes 0.000 description 15
- 101000909198 Homo sapiens DNA polymerase delta catalytic subunit Proteins 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 15
- 230000001419 dependent effect Effects 0.000 description 15
- 239000002609 medium Substances 0.000 description 15
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 14
- 230000003612 virological effect Effects 0.000 description 14
- 230000001965 increasing effect Effects 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 230000001413 cellular effect Effects 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 11
- 238000013518 transcription Methods 0.000 description 11
- 230000035897 transcription Effects 0.000 description 11
- 230000012010 growth Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 9
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 9
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 9
- 230000010261 cell growth Effects 0.000 description 9
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 230000010076 replication Effects 0.000 description 9
- 230000004614 tumor growth Effects 0.000 description 9
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 8
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 102000003952 Caspase 3 Human genes 0.000 description 7
- 108090000397 Caspase 3 Proteins 0.000 description 7
- 108010068150 Cyclin B Proteins 0.000 description 7
- 102000002427 Cyclin B Human genes 0.000 description 7
- 241000341655 Human papillomavirus type 16 Species 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000002354 daily effect Effects 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 238000003757 reverse transcription PCR Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 101150027427 ICP4 gene Proteins 0.000 description 6
- 108010075942 Maturation-Promoting Factor Proteins 0.000 description 6
- 102000011961 Maturation-Promoting Factor Human genes 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 5
- 108060001084 Luciferase Proteins 0.000 description 5
- 108091023040 Transcription factor Proteins 0.000 description 5
- 102000040945 Transcription factor Human genes 0.000 description 5
- 102000004243 Tubulin Human genes 0.000 description 5
- 108090000704 Tubulin Proteins 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 238000006073 displacement reaction Methods 0.000 description 5
- 238000011065 in-situ storage Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- QKHJBWUGXMKHAK-OLZOCXBDSA-N 4-[(2r,3s)-4-(4-hydroxy-3-methoxyphenyl)-2,3-dimethylbutyl]benzene-1,2-diol Chemical compound C1=C(O)C(OC)=CC(C[C@H](C)[C@H](C)CC=2C=C(O)C(O)=CC=2)=C1 QKHJBWUGXMKHAK-OLZOCXBDSA-N 0.000 description 4
- 206010008342 Cervix carcinoma Diseases 0.000 description 4
- 108050006400 Cyclin Proteins 0.000 description 4
- 239000005089 Luciferase Substances 0.000 description 4
- -1 Mai .4) Chemical class 0.000 description 4
- FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical compound CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 description 4
- 102100036691 Proliferating cell nuclear antigen Human genes 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 230000032823 cell division Effects 0.000 description 4
- 210000003793 centrosome Anatomy 0.000 description 4
- 201000010881 cervical cancer Diseases 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000012737 fresh medium Substances 0.000 description 4
- 238000003500 gene array Methods 0.000 description 4
- 238000003119 immunoblot Methods 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 210000003501 vero cell Anatomy 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 241000700199 Cavia porcellus Species 0.000 description 3
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 108700039887 Essential Genes Proteins 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 230000010337 G2 phase Effects 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 3
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 238000000636 Northern blotting Methods 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 101710149951 Protein Tat Proteins 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000009849 deactivation Effects 0.000 description 3
- 230000003828 downregulation Effects 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 229930013686 lignan Natural products 0.000 description 3
- 150000005692 lignans Chemical class 0.000 description 3
- 235000009408 lignans Nutrition 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 230000000394 mitotic effect Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000001566 pro-viral effect Effects 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000011535 reaction buffer Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- NONFLFDSOSZQHR-UHFFFAOYSA-N 3-(trimethylsilyl)propionic acid Chemical compound C[Si](C)(C)CCC(O)=O NONFLFDSOSZQHR-UHFFFAOYSA-N 0.000 description 2
- ORQFDHFZSMXRLM-UHFFFAOYSA-N 4-[4-(3,4-dimethoxyphenyl)-2,3-dimethylbutyl]-1,2-dimethoxybenzene Chemical compound C1=C(OC)C(OC)=CC=C1CC(C)C(C)CC1=CC=C(OC)C(OC)=C1 ORQFDHFZSMXRLM-UHFFFAOYSA-N 0.000 description 2
- 102100031277 Calcineurin B homologous protein 1 Human genes 0.000 description 2
- 101710132601 Capsid protein Proteins 0.000 description 2
- 101710205625 Capsid protein p24 Proteins 0.000 description 2
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 2
- 102000011727 Caspases Human genes 0.000 description 2
- 108010076667 Caspases Proteins 0.000 description 2
- 230000004568 DNA-binding Effects 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 230000037060 G2 phase arrest Effects 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- 244000073231 Larrea tridentata Species 0.000 description 2
- 235000006173 Larrea tridentata Nutrition 0.000 description 2
- 230000027311 M phase Effects 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 102000043276 Oncogene Human genes 0.000 description 2
- 208000002471 Penile Neoplasms Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 101710177166 Phosphoprotein Proteins 0.000 description 2
- 238000010240 RT-PCR analysis Methods 0.000 description 2
- 230000018199 S phase Effects 0.000 description 2
- 101710149279 Small delta antigen Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 230000025084 cell cycle arrest Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 108091092356 cellular DNA Proteins 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000030609 dephosphorylation Effects 0.000 description 2
- 238000006209 dephosphorylation reaction Methods 0.000 description 2
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 108700003601 dimethylglycine Proteins 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000000459 effect on growth Effects 0.000 description 2
- 238000002337 electrophoretic mobility shift assay Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 238000000021 kinase assay Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000011278 mitosis Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 229940078490 n,n-dimethylglycine Drugs 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000031877 prophase Effects 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 108010014186 ras Proteins Proteins 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 206010040872 skin infection Diseases 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 230000005026 transcription initiation Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 230000006490 viral transcription Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- OYIFNHCXNCRBQI-UHFFFAOYSA-N 2-aminoadipic acid Chemical compound OC(=O)C(N)CCCC(O)=O OYIFNHCXNCRBQI-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 229940117976 5-hydroxylysine Drugs 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 101000587984 Arabidopsis thaliana Protein SPOROCYTELESS Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 108091007065 BIRCs Proteins 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 108091028026 C-DNA Proteins 0.000 description 1
- 229940126074 CDK kinase inhibitor Drugs 0.000 description 1
- 101150012716 CDK1 gene Proteins 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102100026550 Caspase-9 Human genes 0.000 description 1
- 108090000566 Caspase-9 Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102100026810 Cyclin-dependent kinase 7 Human genes 0.000 description 1
- 101710106276 Cyclin-dependent kinase 7 Proteins 0.000 description 1
- 102100034770 Cyclin-dependent kinase inhibitor 3 Human genes 0.000 description 1
- 102000005927 Cysteine Proteases Human genes 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 238000000116 DAPI staining Methods 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 101100239628 Danio rerio myca gene Proteins 0.000 description 1
- 102000010170 Death domains Human genes 0.000 description 1
- 108050001718 Death domains Proteins 0.000 description 1
- 101100125027 Dictyostelium discoideum mhsp70 gene Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 108010027044 HIV Core Protein p24 Proteins 0.000 description 1
- 108010085256 HLP-1 polypeptide Proteins 0.000 description 1
- 101150031823 HSP70 gene Proteins 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 108050008339 Heat Shock Transcription Factor Proteins 0.000 description 1
- 102000000039 Heat Shock Transcription Factor Human genes 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 101000945639 Homo sapiens Cyclin-dependent kinase inhibitor 3 Proteins 0.000 description 1
- 101000624643 Homo sapiens M-phase inducer phosphatase 3 Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 101100156155 Human papillomavirus type 16 E7 gene Proteins 0.000 description 1
- 101000954493 Human papillomavirus type 16 Protein E6 Proteins 0.000 description 1
- 101000767631 Human papillomavirus type 16 Protein E7 Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- MFESCIUQSIBMSM-UHFFFAOYSA-N I-BCP Chemical compound ClCCCBr MFESCIUQSIBMSM-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000055031 Inhibitor of Apoptosis Proteins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 108010001831 LDL receptors Proteins 0.000 description 1
- 241000935061 Larrea Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- VEYYWZRYIYDQJM-ZETCQYMHSA-N N(2)-acetyl-L-lysine Chemical compound CC(=O)N[C@H](C([O-])=O)CCCC[NH3+] VEYYWZRYIYDQJM-ZETCQYMHSA-N 0.000 description 1
- PQNASZJZHFPQLE-LURJTMIESA-N N(6)-methyl-L-lysine Chemical compound CNCCCC[C@H](N)C(O)=O PQNASZJZHFPQLE-LURJTMIESA-N 0.000 description 1
- NTWVQPHTOUKMDI-YFKPBYRVSA-N N-Methyl-arginine Chemical compound CN[C@H](C(O)=O)CCCN=C(N)N NTWVQPHTOUKMDI-YFKPBYRVSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 208000009608 Papillomavirus Infections Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 102100037914 Pituitary-specific positive transcription factor 1 Human genes 0.000 description 1
- 101710129981 Pituitary-specific positive transcription factor 1 Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102000008874 Ras-related protein Rap1 Human genes 0.000 description 1
- 108050000825 Ras-related protein Rap1 Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- MJNIWUJSIGSWKK-UHFFFAOYSA-N Riboflavine 2',3',4',5'-tetrabutanoate Chemical compound CCCC(=O)OCC(OC(=O)CCC)C(OC(=O)CCC)C(OC(=O)CCC)CN1C2=CC(C)=C(C)C=C2N=C2C1=NC(=O)NC2=O MJNIWUJSIGSWKK-UHFFFAOYSA-N 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 102000009822 Sterol Regulatory Element Binding Proteins Human genes 0.000 description 1
- 108010020396 Sterol Regulatory Element Binding Proteins Proteins 0.000 description 1
- PCSMJKASWLYICJ-UHFFFAOYSA-N Succinic aldehyde Chemical compound O=CCCC=O PCSMJKASWLYICJ-UHFFFAOYSA-N 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 101710185494 Zinc finger protein Proteins 0.000 description 1
- 102100023597 Zinc finger protein 816 Human genes 0.000 description 1
- QWXOJIDBSHLIFI-UHFFFAOYSA-N [3-(1-chloro-3'-methoxyspiro[adamantane-4,4'-dioxetane]-3'-yl)phenyl] dihydrogen phosphate Chemical compound O1OC2(C3CC4CC2CC(Cl)(C4)C3)C1(OC)C1=CC=CC(OP(O)(O)=O)=C1 QWXOJIDBSHLIFI-UHFFFAOYSA-N 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000006909 anti-apoptosis Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003622 anti-hsv Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 239000012965 benzophenone Substances 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000012159 carrier gas Substances 0.000 description 1
- 108700021031 cdc Genes Proteins 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000007881 chronic fibrosis Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010205 computational analysis Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 235000012605 creosote bush Nutrition 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229950006137 dexfosfoserine Drugs 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 101150052825 dnaK gene Proteins 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000010230 functional analysis Methods 0.000 description 1
- UHBYWPGGCSDKFX-VKHMYHEASA-N gamma-carboxy-L-glutamic acid Chemical compound OC(=O)[C@@H](N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-VKHMYHEASA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 102000057041 human TNF Human genes 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- FBKDEECWCACPLH-UHFFFAOYSA-N methyl 2-oxo-1,3-dihydroindole-4-carboxylate Chemical compound COC(=O)C1=CC=CC2=C1CC(=O)N2 FBKDEECWCACPLH-UHFFFAOYSA-N 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 230000012312 microtubule nucleation Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000031945 negative regulation of viral transcription Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 108091008819 oncoproteins Proteins 0.000 description 1
- 102000027450 oncoproteins Human genes 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- USRGIUJOYOXOQJ-GBXIJSLDSA-N phosphothreonine Chemical compound OP(=O)(O)O[C@H](C)[C@H](N)C(O)=O USRGIUJOYOXOQJ-GBXIJSLDSA-N 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000028617 response to DNA damage stimulus Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 102220002645 rs104894309 Human genes 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- FLNVBBPBGKOJHN-KKAOYSRWSA-N sivmac Chemical compound O=C([C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)[C@@H](C)CC)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(O)=O FLNVBBPBGKOJHN-KKAOYSRWSA-N 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000004085 squamous epithelial cell Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 108700004027 tat Genes Proteins 0.000 description 1
- 101150098170 tat gene Proteins 0.000 description 1
- ORQFDHFZSMXRLM-IYBDPMFKSA-N terameprocol Chemical compound C1=C(OC)C(OC)=CC=C1C[C@H](C)[C@H](C)CC1=CC=C(OC)C(OC)=C1 ORQFDHFZSMXRLM-IYBDPMFKSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 238000012384 transportation and delivery Methods 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 208000024719 uterine cervix neoplasm Diseases 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the invention relates to the use of nordihydroguaiaretic acid derivatives, in particular derivatives containing substituents of naturally occuring amino acids, for the treatment of tumors and viral infections.
- Carcinogenesis is a multistage event affected by a variety of genetic and epigenetic factors and is typified by the outbreak of uncontrolled cell growth originated from different tissues.
- a universal goal for anticancer research lies in the development of a clinical treatment that is highly effective in curtailment of tumor growth, non-toxic to the host, and is affordable for most patients.
- Drugs that focus on the inhibition of targets that are unique to dividing cells should be effective chemofherapeutic agents without the risk of substantial side effects.
- Cells pass through many checkpoints as they proceed through the cell cycle. Certain criteria must be met in order to pass each of these checkpoints. In the G2/M transition, the most essential regulator is the cyclin- dependent kinase CDC2.
- This kinase binds tightly to the regulatory protein cyclin B, and this complex, also called the maturation promoting factor (MPF), is responsible for stimulating a myriad of events that lead to the cell's entry into early prophase (1).- Not surprisingly, the loss or deactivation of either component ofthe MPF will block cellular progression out of G2.
- the expression and activity ofthe MPF is regulated at different levels. Cyclin B protein levels slowly rise through the Gl and S phases ofthe cell cycle, peak during the G2 to M phase transition, and drop sharply during mitosis (2).
- the CDC2 protein on the other hand, is always present during the cell cycle, although levels rise slightly in the last stages ofthe G2 phase (3).
- the activity ofthe protein is dependent on the association with the appropriate cyclin, as well as on the dephosphorylation of its inhibitory sites by the phosphatase CDC25C (4,5). It has been shown that the failure of this dephosphorylation initiates G2 arrest in response to DNA damage by radiation or chemical action. Recent evidence also suggests that any remaining active CDC2 may be transported outside the nucleus following DNA damage (6).
- NDGA plant lignan nordihydroguaiaretic acid
- HPV infection Human papillomavirus (HPV) infection causes unregulated cell growth in many types of squamous epithelial cells, resulting in afflictions ranging from benign pallilomae (warts) to cervical, penile and mouth cancer.
- benign pallilomae warts
- cervical, penile and mouth cancer The strong association of these cancers with HPV and the widespread occurrence of infection denotes the importance of developing an anti HPV therapy.
- viruses including those replicatively active mutants, are host dependent. They require the participation of certain cellular factors for supporting viral growth. Host cellular factors, unlike viral proteins, are not under mutational pressure and are in general, structurally invariable. Thus, compounds that block the usage of these cellular factors at different stages of the viral life cycle are likely to be good candidates as mutation insensitive antiviral drugs.
- cellular factors unlike viral proteins, are not under mutational pressure and are in general, structurally invariable. Thus, compounds that block the usage of these cellular factors at different stages of the viral life cycle are likely to be good candidates as mutation insensitive antiviral drugs.
- NDGA 3'-0 -methylated NDGA (i.e. Mai .4), isolated from Creosote bush (Larrea tridentata) can specifically block basal HIV transcription, Tat-regulated transactivation, and HIV replication in human cell culture(8, 12, 13).
- Mal.4 exerts its effects by interfering with the binding of transcription factor Spl to the promoter ofthe HIV pro viral template.
- the target of Mal.4 is mapped to nucleotides -87 to -40, the Spl binding sites of the HIV long terminal repeat (LTR).
- LTR HIV long terminal repeat
- Survivin is an inhibitor of apoptosis that is abundantly expressed in many human cancers (35), but not in normal adult human tissue, and is considered a possible modulator ofthe terminal effector phase of cell death/survival. (36). Survivin is expressed in G 2 -M in a cell cycle-dependent manner, binding directly to mitotic spindle microtubules. It appears that survivin phosphorylation on Thr34 may be required to maintain cell viability at cell division (37), and expression of a phosphorylation-defective survivin mutant has been shown to trigger apoptosis in several human melanoma cell lines (38).
- Phosphorylated survivin acts on the caspase pathway to suppress the formation of caspase-3 and caspase-9, thereby inhibiting apoptosis.
- page 10 presents an outline of apoptosis signalling pathways.
- compounds that reduce the expression of survivin will be expected to increase the rate of apoptosis and cell death.
- CDC-2 has been shown to be necessary for survivin phosphorylation (37).
- novel nordihydroguaiaretic acid derivatives are provided that inhibit tumor growth.
- nordihydroguaiaretic acid derivatives is meant compounds ofthe structure
- Amino acid substituents are intended to include, inter alia, alanine, arginine, asparagine, aspartate, cysteine, glutamate, gluamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, 5-hydroxylysine, 4- hydroxyproline, thyroxine, 3-methyll ⁇ istidine, ⁇ -N-methyllysine, ⁇ -N,N,N- trimethyllysine, aminoadipic acid, ⁇ -carboxyglutamic acid, phosphoserine, phosphothreonine, phosphotyrosine, N-methylarginine, and N-acetyllysine.
- Particularly preferred compounds for use according to the invention are
- the method should be especially effective against rapidly proliferating cell types containing the cyclin dependent kinase CDC2. It is a further object ofthe invention to provide a method of inliibiting CDC2 in a eukaryotic cell cycle, particularly in an animal cell, more particularly in a mammalian cell, and most particularly in a human cell.
- Tumors to be treated include any tumor that is sensitive to the above- mentioned compounds used according to the methods ofthe invention. In particular, this includes rapidly dividing cancerous and benign tumors that are sensitive to inhibition ofthe cyclin-dependent kinase CDC2 cycle.
- cancerous tumor is intended to include any malignant tumor that may or may not have undergone metastasis.
- noncancerous tumor is intended to include any benign tumor.
- Tumors to be treated include those that are known to be of viral origin, as well as those that are not of viral origin.
- the compositions and methods ofthe invention are expected to be particularly useful in the treatment of solid tumors.
- HPV-induced tumors include in particular, but are not limited to, cervical, oral, penile and head and neck cancers that are associated with HPV infection.
- the method comprises local application of nordihydroguaiaretic acid derivatives, in particular tetra-O-methyinordihydroguaiaretic acid (M 4 N) and tetraglycinal nordihydroguaiaretic acid (G 4 N), to cancerous and noncancerous HPV-induced tumors.
- M 4 N tetra-O-methyinordihydroguaiaretic acid
- G 4 N tetraglycinal nordihydroguaiaretic acid
- Preferred for use in this method are compounds in which the amino acid substituents Ri , R R 3 and R 4 are identical.
- the inventors have found that the nordihydroguaiaretic acid derivatives ofthe invention downregulate survivin mRNA and protein levels and activate both CDC-2 and the caspase pathway, thereby increasing the level of apoptosis in cell populations where survivin is expressed.
- This method should provide a treatment for cancers where survivin is expressed by suppressing or eliminating survivin expression, thereby increasing the rate of apoptosis.
- M 4 N, G 4 N and other derivatives will be administered by local injection into the tumors, generally along with pharmaceutically acceptable diluents, excipients and carriers.
- M 4 N is injected into tumors in the form of a DMSO solution, and G 4 N is administered in PBS solution.
- G 4 N will complement the use of M 4 N, particularly in larger tumors (> 2 cm 3 ), due to its water solubility, which allows it to spread to a larger region ofthe tumor.
- Other water-soluble and water-insoluble nordihydroguaiaretic acid derivatives can be similarly employed, according to the invention. These may also be employed in lipid based formulations for systemic delivery, as known and used in the art.
- diluents such compounds as will be known to persons of skill in the art as being compatible with M 4 N, G 4 N and other similar derivatives and suitable for local administration to a human or other mammal according to the invention.
- the amount of compound administered to obtain the desired treatment effect will vary but can be readily determined by persons of skill in the art.
- the amount of dosage, frequency of administration, and length of treatment are dependent on the circumstances, primarily on the size and type of tumor. However, dosages of from 10 mg to 20 mg of either M 4 N alone or with similar amounts of G 4 N per gram tumor weight at intervals from daily to weekly or less frequently may be mentioned for purposes of illustration.
- Administration of 50 ⁇ l to 100 ⁇ l of M N dissolved in DMSO at a concentration of 200 mg/ml, either alone or in combination with G 4 N, is expected to be effective in many cases for tumors of 1-1.5 cm 3 .
- FIG. 1A HPV-16 LCR showing region of E 6 /E 7 promoter (pPV16P97) and the binding site for Spl protein.
- FIG. 2B The effect of M 4 N on the E 6 /E 7 promoter activity in C-33A cells. (Inhibition of E 6 /E 7 promoter driven luciferase gene transcription by different concentration of M 4 N)
- Figures 3A-3C Inhibition of Viral E 6 and E 7 RNA Transcripts by 40 ⁇ M M 4 N.
- the RTPCR samples were removed after increasing cycles of amplification and resolved on an agarose gel.
- the gel photographs (3 A and 3B) indicate these cycles, the presence of (+) or absence (-) of M N in the growth media, and two digests of a pGMT vector used as size markers.
- the amplification map (2C) indicates the two expected size products ofthe amplification, resulting from the alternate splicing ofthe early viral RNA transcript.
- FIGS 5A-5B Effect of M 4 N on gene expression in C3 cells as examined by the GENE Assay analysis.
- 5A GENE expressed in C3 cells after > 2 hours of DMSO treatment (C3 DMSO).
- 5B GENE expressed in C3 cells after > 2 hours of M 4 N treatment using DMSO as solvent (C3 M 4 N).
- FIGS 6A-6B Visual observations of tumor-bearing mice following M 4 N treatment.
- 6 A Mice bearing single tumors were treated with in situ injection of DMSO (#3) or M 4 N (#7). In situ injection of M 4 N was also made to one of the two tumors grown in mouse #9. 6B. M 4 N treated tumor (white scar) with untreated tumor from the same mouse, #9 as described in Table 2.
- FIG. 7 Histopathology Effect of M 4 N and M N/G N on Tumor Growth in Mice.
- First column from the panel presents the large size of tumors from mouse #4, 10, 12, following DMSO treatment (CON) as compared to the relatively small drug treated (M f N or M 4 N/G 4 N) lesions from mouse #12, 10, 27 and 20 (M 4 N).
- the subsequent photographs are examples of these tumors examined at 100X magnification (A, B, C, DMSO treated, D untreated, E, F, G, H, M 4 N or M 4 N/G 4 N treated) mice (Table 1 and Table 2).
- FIG 8. HSV-1 replication in the absence of drugs (HSV-C, HSV-SC), in the presence of ineffective drugs (ABDS t [' ⁇ SV-ABDSi”], ABDS 2 ["HSV- ABDS 2 "])and in the presence of effective drags (M 4 N ["HSV-4N"] and ACV ["HSV-ACV”]).
- CEM-T4, C33a, and TC-1 cells were treated with different concentrations of M 4 N.
- the number of cells present at the initiation ofthe experiment is indicated as Day 0.
- the number of viable cells were counted and plotted versus the M N concentration, (e) C3 cells were split into T-25 flasks with 5 X 10 3 cells per flask and given either M 4 N in 1% DMSO in media or 1% DMSO in media alone (first media change).
- M- D fresh media containing only 1% DMSO
- second media change The cells were counted daily and plotted versus the time of treatment.
- FIG. 10 Cells Treated With M 4 N Arrest in G2/M.
- C3 cells (a), C33a cells (b), CEM-T4 cells (c), and TCI cells (d) were grown for three days in media containing either 1% DMSO or 1% DMSO withM 4 N (M 4 N).
- the cells were trypsinized, fixed with ethanol, stained with propidium iodide, and were subsequently analyzed by flow cytommetry.
- the data is displayed as number of cells (3-5 X 10 total cells) versus propidium iodide stain intensity.
- the indicated stages ofthe cell cycle are labeled and correspond to the relative cellular DNA compliment as determined by staining intensity.
- FIG. 11 C3 Cells Treated With 40 ⁇ M M 4 N Demonstrate G2 Cell Structures. C3 cells were grown on coverslips for three days in media containing either 1% DMSO (Control) or 1% DMSO with 40 ⁇ M M 4 N (M 4 N). Samples were fixed with ethanol and incubated with antibodies against ⁇ (green) and ⁇ (orange) tubulin (a) or with the DAPI DNA stain (b). Cells were examined by fluorescence microscopy. Figure 12. CDC2 and Viral Oncogenes are Reduced by M 4 N.
- C3 cells were grown for different amounts of time (numbers are in hours) in media containing either 1% DMSO (D) or 1% DMSO with 40 ⁇ M M 4 N (M). After the specified times, total protein or total RNA was isolated from the cells.
- Western blots (a - top two panels) were performed using antibodies against CDC2 or cyclin B with the same nitrocellulose filter.
- Kinase assays (a - bottom two panels) were performed, following immunoprecipitation with antibodies to cyclin B, by incubation with ⁇ - P ATP and histone HI . The coomassie stain ofthe PAGE gel is included as control for loading. Kinase assays for 24 and 72 hour drug treatments were performed separately.
- Northern blots were performed on total RNA extracts. Filters were incubated overnight with random-primed 32 P-labeled DNA for CDC2 or GAPDH, washed, and exposed to film for three days. The same filter was used to test CDC2 and GAPDH RNA.
- rtPCR analysis was performed on total RNA extracts with primers hybridizing to regions within either HPV- 16 E7 or GAPDH. Both primer pairs were used in the same reactions, and the products were analyzed by agarose gel electrophoresis.
- FIG. 13 Electrophoretic mobility shift assay (EMS A) of G 4 N interaction with the HIV Spl-binding sites (-87 to -49).
- EMS A Electrophoretic mobility shift assay
- Lane 1 template alone; lane 2, template plus 0.1 ⁇ g Spl-167D plus 100-fold excess of unlabeled template; lane 3, template plus 0.1 ⁇ g Spl-167D; lanes 4-10, Spl/DNA complex challenged with increasing concentrations of G N (0.25 to 1.75 mM); lane 11, template incubated in reaction buffer containing 1.75 mM G 4 N.
- C Spl-167D displacement of G 4 N bound to template.
- Lane 1 template alone; lanes 2-4, template plus increasing amounts of Spl-167D (0.075,
- FIG. 15 SIV production with presence of G 4 N. 10 7 174 x cells, a human T-cell lymphoma cell line, were mixed with a 24 hrs. harvest stock of SIV mac 239 (4 ng of p27) for two hours at 37. Cells were resuspended and 1 x 10 5 cells in 100 ⁇ l medium were added to each well of three 96-well plates. Various concentrations of G 4 N from a freshly made stock were prepared and added to each ofthe six designed well. Culture supematants were collected after four and eight days for viral production analysis. Viral production was assayed by a modified p27 capsid protein antigen capture ELISA as described in experimental section.
- Figure 16 Inhibition of HIV p24 antigen production in H9 cells by G 4 N. Inhibition in percentage was calculated by comparing p24 level from an average of two duplicate cultures of G 4 N treated and not treated H9 cells 9 days following viral infection with a AZT resistant HIV strain, HIV-IRTMF.
- FIG. 17 RT-PCR Analysis of Survivin Gene Expression, (a) Top: Survivin gene expression in C3 cells treated with 40 ⁇ M M N for 24 hours and 72 hours, respectively (lanes 3 and 4) and in the untreated controls (lanes 1 and 2). Bottom: the corresponding GAPDH controls. Band intensities were quantitated with Scion Image, (b) Survivin RT-PCR product signals were normalized to those ofthe GAPDH controls and plotted.
- FIG. 19 Immunoblot analysis of caspase-3 cleavage in C3 cells treated with M N for 72 hours, (a) Western blot of caspase-3 showed cleavage ofthe 32 KD procaspase-3 and the formation ofthe active 20 KD cleaved product, (b) Band intensities were quantitated and plotted against M N concentration.
- NDGA derivatives were synthesized chemically (7).
- Cell line C3 is a HPV16E + L plus activated Ras transformed cell line of C57 BL/6kh origin provided by W. Martin Kast of Loyola University Medical Center, Chicago, Illinois, U.S.A. It is maintained and cultivated as described by Greenstone et Al. (18) and Feltkamp et al. (19, 20).
- Nitrogen gas was used as a carrier gas and the flow rate was kept constant at 14.0 ml/min.
- the retention time (t R ) was measured under the following conditions: injector temperature 260°C, isothermal column temperature 280°C.
- Gas chromatography and low resolution mass spectral analyses were performed on a Hewlett-Packard 5890 Series II instrument equipped with a Hewlett-Packard 5971A Mass Selective Detector and a capillary HP-1 column. Separations by medium-pressure liquid chromatography (MPLC) were performed at a flow rate of 120 ml/h by use of a Jasco Model 880-PU intelligent HPLC pump.
- MPLC medium-pressure liquid chromatography
- the MPLC packing material Reversed Phase Silica Gel C18 (particle size 0.035-0.070 mm), was purchased from Knauer Co. Purification by gravity column cliromatography was carried out by use of Merek Reagents Silica Gel 60 (particle size 0.063-0.200 mm, 70-230 mesh ASTM).
- JR Infrared
- FT-LR Bomem Michelson Series FT-LR spectrometer
- the wave numbers reported are referenced to the polystyrene 1601 cm "1 absorption. Absorption intensities are recorded by the following abbreviations: s, strong; m, medium; w, weak.
- Proton NMR spectra were obtained on a Varian Unity-400 (400 MHz) spectrometer by use of D20 as solvent and 3-(trimethylsilyl)propionic acid, sodium salt as internal standard.
- Carbon- 13 NMR spectra were obtained on a Varian Unity-400 (100 MHz) spectrometer by use ofD 2 0 as solvent.
- Carbon- 13 chemical shifts are referenced to the center ofthe 3-(trimethylsilyl)propionic acid, sodium salt singlet (6 0.0 ppm). Multiplicities are recorded by the following abbreviations: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; J. coupling constant (hertz). High-resolution mass spectra were obtained by means of a JEOL JMS-HX110 mass spectrometer. meso- 1 ,4Bis[3 ,4(dimethyleminoacetoxy)phe 3 S-dimethylbutane Hydrochloride Salt (2).
- C33 A is a cervical tumor cell line (ATCC accession no. HTB-31) that does not contain any integrated HPV DNA, but has transcription factors necessary for a robust expression ofthe HPV early gene promoter.
- DMSO dimethyl sulfoxide
- HPV-16 transformed immortal mouse epithelial cells were plated at a density of 10 5 cells per vial. After 24 hours, l A ofthe vials were given growth media containing 40 ⁇ M M 4 N dissolved in 1% DMSO while the other half were given growth media containing only 1% DMSO. The results are shown in Figure 4A. Within 24 hrs a difference in cell morphology between drug treated and control C3 cells was observed. The growth and division ofthe drug treated cells was markedly reduced in comparison to the untreated control, while the fraction of viable cells compared to the total cell count remained constant for both drug treated and DMSO only control cells. This indicates that M 4 N dramatically reduces cell division.
- C3 cells were plated at a density of 10 4 cells per vial.
- 2/3 ofthe vials were given growth media supplemented with 40 ⁇ M ⁇ N in 1% DMSO.
- the remaining vials were given growth media containing only 1% DMSO.
- l A ofthe vials that had received M 4 N in their growth media were washed and media containing only 1% DMSO was added.
- the other 2/3 ofthe cell vials were washed and replaced with the same media administered before.
- the results, shown in Figure 4B indicate that the rate of cell growth was not notably increased in M 4 N treated sample following the change to drag-free media, indicating that M 4 N continues to significantly reduce cell division even after its removal from the extracellular environment.
- Example 4 Analysis of cellular gene expression in C3 cells before and after 72 hrs of drug treatment.
- the computer print outs showing differentially expressed genes (C 3 M 4 N/C 3 DMSO >10 and C 3 DMSO/C 3 M 4 N >10) were listed for examination.
- Image files in TLFF format and data files in MS excel format are kept on ZIP diskette.
- Gene names and clone ID numbers are available for obtaining Image clones for future northern blot confirmation.
- Cyclin-dependent kinase 7 (5%) 100% Human cytokine receptor (2%) 100% Proliferating cell nuclear antigen, PCNA (1%) 100% Human TNF-related Apoptosis AP0 2 (3%) 100% Cysteine protease (7%) 100%
- E 6 /E 7 level was found to be similar with those in control cells while after 4.5 hrs, E 6 /E 7 were no longer detectable by RT-PCR (10).
- Gene expressions with 9600 gene arrays can be repeated with RNA isolated from these short-time treated cells (1 hour and 5 hours) in order to further pin down the initial cellular effects ofthe drug.
- mice Thirty six C57M-16 NCR mice were injected with 5 x 10 5 C3 cells between the shoulders on the backs ofthe mice. Twenty four ofthe mice developed tumors within 20 days. Daily injection (50 ⁇ .1-100 ⁇ l of M 4 N or
- M 4 N/G 4 N (200 mg/ml M 4 N in DMSO, 200mg/ml G 4 N in PBS) showed profound effect in tumor growth in animals, as shown in Tables 1 and 2, Fig. 6 and 7. Table 1. M*N and G 4 N Effect on Growth of Single Tumors Developed in Mice
- mice developed tumors. Their lesion sizes were measured by dial caliper. These mice were shaved, weight and treatment begun (Day 1). Four mice were sequestered as controls. Control mice received 50 ⁇ l DMSO injected intratumorally daily. Experimental mice (10) received 50 ⁇ l 4 N dissolved in DMSO(200mg/mL). An additional 10 mice received M 4 N treatments for 8 days followed by G 4 N treatments (50 ⁇ l, 200mg/ml in PBS) daily for 8 days. Injections were made to several regions of tumor. Mice anesthetized with ether or metaphane prior to injection.
- mice All treated mice, controls (mouse numbers 1-4) and experimental mice (mouse numbers 6, 7, 9, 10, 11, 12, 14, 15, 16, 17 M 4 N numbers 18-22, 24, 26-29 M 4 N/G 4 N) exhibited swelling. Measurements of lesion sizes were made by dial caliper. Some mice experienced mild bleeding due to injection. The treatment regimen and results were as follows:
- Day 15 One M 4 N treated mouse (#17) died due to overdose of anesthesia/handling. The skin at the lesion site of #17 cracked with the "dried-out tumor" showing. It was dissected, and lesion excised and weighed.
- Day 16 Four more M N treated mice (#6, 14, 15, 16), three M 4 N/G 4 N treated mice (#19,21,28) and one control mouse (#2) were euthanized, dissected and weighed. Remaining control mice (#1, 3, 4) were examined non-invasively and were carrying tumors. Day 21 : Tumor sizes from control mice were measured by dial caliper.
- mice The skin at the lesion sites of mouse #10 and #12 (M 4 N treated regions) cracked with the "dried-out tumor" showing.
- Day 24 Mouse #7 skin recovered completely. The experiment was terminated on this date. All remaining mice, M 4 N treated (#7, 9, 10, 11, 12) and M 4 N/G 4 N treated (#18, 20, 24, 26, 29) were euthanized, dissected, examined and weighed.
- Tables 1 and 2 and Figures 5 and 6 The effects of M 4 N and M 4 N/G 4 N on C3 tumor growth in mice are summarized in Tables 1 and 2 and Figures 5 and 6.
- Table 1 shows the drug • effect on C3 cell growth in mice carrying single tumors.
- the average weight of four excised tumors ofthe control group was 1.48 g while weights of lesions from M N treated and M 4 N/G 4 N treated were 0.142 and 0.51 g respectively.
- Drug treated lesions consisted mainly of dried out necrotic cells (Fig. 6). Tumors from the control group appeared homogenous and contained actively growing cells.
- Table 2 shows the drug effect on C3 tumor growth in mice carrying multiple tumors. In this study, drag was injected into one ofthe tumors.
- the average weight of untreated tumors was 1.77 g while that of M N treated lesions was 0.15 g. Similar results were obtained following M N/G 4 N inj ection — the average weight of untreated tumors was 1.27 g, while that ofthe drag treated lesions was only 0.103 g. The body weight changes of all mice during the entire experimental period appeared insignificant (Table 1 and 2).
- Drug treated (M 4 N) and DMSO vehicle-treated or untreated tumors (CON) from two groups of mice were prepared for histopathology examination.
- the excised tumors were immediately fixed and then stored in 4% formaldehyde in phosphate buffered saline.
- the fixed tissue was then dehydrated through a series of graded alcohols and xylene and embedded in paraffin.
- the paraffin tissue blocks were thin sectioned and stained for microscopy with hematoxylin and eosin. Histopathology studies showed that the control tumors were unaffected by DMSO treatment and continued to grow.
- the drag M 4 N was also tested in inhibition of HSV-1 replication in skin infections in guinea pigs. Guinea pig skin was pinched with needles and HSV-1 suppression was applied topically to infect each pricked area. M 4 N was then applied to the pricked infected area following infection daily for 6 days.
- HSV-1 HSV-C, culture supernatant, or isolated HSV in saline, HSV-SC.
- HSV-SC culture supernatant, or isolated HSV in saline, HSV-SC.
- HSV-SC culture supernatant, or isolated HSV in saline, HSV-SC.
- test compounds ABDSi, ABDS 2 , ACV and M 4 N (4N) in 60 mg/ml of DMSO were applied to each punched infected region of an area, five times per day for six days.
- ABDS 1 and ABDS were included as negative controls.
- M 4 N is a hydrophobic compound and is exceedingly soluble in DMSO (200 mg/ml). Therefore only a small volume ofthe drag solution is needed for injection in order to achieve effective dosage ofthe drag.
- DMSO 200 mg/ml
- daily injection of 50 ⁇ l to 100 ⁇ l for several days was sufficient to completely stop tumor growth in mice.
- DMSO should be safe as a vehicle for drug delivery when only small volume of it will be used (23). 2)
- a majority ofthe drug residue remains insoluble and concentrated in the tumor areas, and does not enter the circulatory system, thus whole body toxicity is avoided.
- enough drug remains within the tumor to suppress its growth, continued injection of drug is unnecessary after relatively few treatments.
- tumor cells continued to die even after discontinuation of M 4 N injections.
- tumor size becomes the determining factor for the required amount of drug to be administered.
- the difference between whole body weights of a human vs. a mouse becomes irrelevant.
- 20 mg/day for 10 days were more than sufficient to eliminate tumors.
- M 4 N may therefore block their transcription. This hypothesis was tested by examining the antiproliferative effect of M 4 N on a number of different cell lines. Low concentrations (10 ⁇ M) ofthe parent compound, NDGA, have previously been shown to induce apoptosis in mammalian cells (24). This effect, however, can be circumvented by blocking one ofthe catechol oxygens or the addition of a hydrophilic group to NDGA (25).
- the centrosomes of M 4 N treated cells are duplicated but still located next to each other in the nucleus ofthe cell. Since centrosomes separate during early prophase, it can be concluded that these cells have not begun mitosis.
- the gamma tubulin staining ofthe control cells has the diffuse pattern characteristic of Gl or S phase (29). A lack of cliromatin condensation in the M 4 N treated cells was also observed with DAPI staining ( Figure 12b), additional evidence that the cells have not moved forward out of G2 phase (30).
- the use ofthe C3 cell line allows us an additional control for analysis ofthe mechanism of M 4 N mediated cell cycle arrest since other Spl- dependent gene promoters are also likely to be inhibited by M 4 N treatment.
- This possibility was examined in C3 cells by analyzing the effect of M 4 N on transcription from the Spl dependent HPV-16 E 6 /E 7 promoter.
- rtPCR analysis of RNA isolated from C3 cells treated with 40 ⁇ M M 4 N for 5 to 72 hours demonstrated a clear reduction in the levels ofthe E 7 transcript (Figure 12c).
- GAPDH was again used as an internal control in this experiment, and its levels were unaffected by drag treatment.
- Spl family proteins induce bends toward the major groove of DNA upon binding (33).
- the zinc finger domain ofthe Spl protein is responsible for the binding ofthe GC Box sequence 5'-GGGGCGGGG-3'. From computational analysis, it was determined that G 4 N, the aminoester derivative of NDGA, could form a stable complex with such a sequence in the major groove.
- G 4 N can serve as an Spl blocker as well as an Spl displacer
- DNA binding domain of recombinant Spl protein was next added and incubated for additional 30 min in the presence of a large excess of BSA protein.
- the recombinant SP1-167D was first allowed to bind DNA, G 4 N was then added at the second step ofthe incubation.
- the G 4 N and Spl-167D concentrations and, the incubation and gel electrophoresis conditions were identical in both studies (experimental section). As shown in Figure 13, in either case, G 4 N was found to be able keep DNA from interacting with Spl-167D protein.
- methylated NDGA derivatives can block Spl binding to the enhancer sites of a variety of viral promoters including HIV, ICP4 of HSV, E 6 /E 7 gene of HPV (8, 9, 10).
- G 4 N effect on the Tat-transactivation of HTV promoter activity in Cos cells by the SEAP assay as previously described. Basal level ofthe HIV LTR driven SEAP. expression was previously found to be barely detectable in Cos cells. There were 60-fold or more increase in SEAP expression when Cos cells were cotransfected with the CMV promoter driven Tat gene (8).
- Such Tat-driven transactivation ofthe HIV LTR promoter activity was previously shown to be Spl regulated (7, 8).
- C3 cells (5xl0 6 ) were seeded in 150-mm plates and allowed to attach to the plates. Twenty-four hours after seeding, cultures were washed twice with PBS and treated with M 4 N dissolved in 1% DMSO mixed with the growth medium.
- Cell extracts and immunoblotting were lysed in lysis buffer containing 50 mM HEPES pH 7,250 mM NaCl, 0.1% (v/v) Nonidet P-40, 10% glycerol, lmM DTT, and 50 ⁇ l/ml protease inhibitor cocktail (Sigma). Protein concentration ofthe extract was determined by the Bradford assay (Bio-Rad Laboratories), and then 50 ⁇ g of protein was separated by SDS-PAGE and electrotransferred to nitrocellulose membrane (ECL). Membranes were incubated with primary antibodies against Survivin (Santa Craz Biotechnology) and caspase- 3 (Santa Cruz Biotechnology). Blots were then incubated with anti-rabbit biotin- conjugated secondary antibody and then with Avidx-APTM streptavidin-alkaline phosphatase, and detected with CSPD® substrate (Tropix).
- RT-PCR analysis mRNA was isolated by the guanidinium thiocyanate and phenol method from the cultured cells as described in Molecular Cloning (40). A 343-base pair RT-PCR product was generated by using the survivin-sense oligonucleotide primer 5'-GCATCGCCACCTTCAAGAACTGGCCC-3' and the survivin-antisense oligonucleotide primer 5'-
- GAPDH sense and anti-sense primers 5'-GAATCTACTGGCGTCTTCACC-3' and 5'- GTCATGAGCCCTTCCACGATGC-3 ' were used to generate a 238-base pair RTPCR product as a control.
- mRNA aliquots were incubated in 20 ⁇ l reaction buffer containing 1 U or rRNAsin and DNAse at 75°C for 5 minutes followed by reverse transcription reaction with MMLV (Promega).
- the c-DNA products obtained were amplified under the PCR conditions: 55°C for 55 seconds, 60°C for 55 seconds, and 72°C for 1 minute for 30 cycles.
- PCR products were separated by electrophoresis on a 1.8% agarose gel containing ethidium bromide and photographed under UV. The bands were quantitated by Scion Image and the signal intensities ofthe survivin PCR reaction products were normalized to those ofthe GAPDH PCR products to generate a survivin gene down-regulation graph.
- M 4 N treatment we treated the cells with 40 ⁇ M M 4 N for 24 hours and 72 hours. As shown in Figure 1, treatment of cells with M 4 N resulted in a significant decrease in survivin gene expression in a time-dependent manner. Treatment with 40 ⁇ M M N for 24 hours and 72 hours resulted in 65% and 80% reduction in survivin expression, respectively. Untreated cells did not show any reduction in survivin gene expression.
- Survivin protein was also shown by immunoblotting to be downregulated by 72 hours of N treatment. This downregulation was dosage-dependent ( Figure 2).
- G. Spl can displace GHF-1 from its distal binding site and stimulate transcription form growth hormone gene promoter. Moll Cell. Biol. 1990, 10, 1811. 17. Phelps, W. C, Yee, C. L., Munger, K. and Howley, P. M. (1988) The Human Papilloma Virus Type 16 E7 Gene Encodes Transactivation and Transformation Functions Similar to Those of Adeno viras E/A. Cell 53, 539-547.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/851,425 US6608108B2 (en) | 1999-10-15 | 2001-05-09 | Method for treatment of tumors using nordihydroguaiaretic acid derivatives |
US851425 | 2001-05-09 | ||
PCT/US2002/014374 WO2002089795A1 (en) | 2001-05-09 | 2002-05-08 | Method for treatment of tumors using nordihydroguaiaretic acid derivatives |
Publications (3)
Publication Number | Publication Date |
---|---|
EP1392293A1 true EP1392293A1 (en) | 2004-03-03 |
EP1392293A4 EP1392293A4 (en) | 2005-05-25 |
EP1392293B1 EP1392293B1 (en) | 2016-10-26 |
Family
ID=25310742
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02739227.3A Expired - Lifetime EP1392293B1 (en) | 2001-05-09 | 2002-05-08 | Method for treatment of tumors using nordihydroguaiaretic acid derivatives |
Country Status (8)
Country | Link |
---|---|
US (3) | US6608108B2 (en) |
EP (1) | EP1392293B1 (en) |
JP (2) | JP2004534025A (en) |
CN (1) | CN1525857B (en) |
AU (1) | AU2002311890C1 (en) |
CA (1) | CA2447045A1 (en) |
SG (1) | SG169224A1 (en) |
WO (1) | WO2002089795A1 (en) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6365787B1 (en) * | 1994-09-30 | 2002-04-02 | The Johns Hopkins University | Compounds for the suppression of HIV TAT transactivation |
US6608108B2 (en) * | 1999-10-15 | 2003-08-19 | Johns Hopkins University | Method for treatment of tumors using nordihydroguaiaretic acid derivatives |
US7728036B2 (en) | 2003-05-20 | 2010-06-01 | Erimos Pharmaceuticals, Llc | Methods for delivery of catecholic butanes for treatment of tumors |
JP2007500229A (en) * | 2003-05-20 | 2007-01-11 | ジョンズ・ホプキンズ・ユニバーシティ | Methods and compositions for administration of catecholbutane for the treatment of tumors |
US20060141029A1 (en) * | 2003-05-20 | 2006-06-29 | Erimos Pharmaceuticals Llc | Methods and compositions for delivery of catecholic butanes for treatment of diseases |
CN1984921B (en) | 2003-06-03 | 2010-06-16 | Isis药物公司 | Modulation of survivin expression |
WO2005112924A2 (en) * | 2004-04-27 | 2005-12-01 | California Institute Of Technology | Methods of treating cancer by inhibiting histone gene expression |
CN100440843C (en) * | 2004-05-12 | 2008-12-03 | 华为技术有限公司 | Ring net and method for realizing service |
US8440648B2 (en) * | 2004-07-20 | 2013-05-14 | Erimos Pharmaceuticals Llc | Methods and compositions for treatment of intraepithelial neoplasia |
WO2006069192A1 (en) * | 2004-12-22 | 2006-06-29 | The Gillette Company | Reduction of hair growth with survivin inhibitors |
CN101150955B (en) * | 2005-01-27 | 2013-04-17 | 埃里莫斯医药品有限公司 | Oral formulations for delivery of catecholic butanes including NDGA compounds |
US20080096967A1 (en) * | 2005-01-27 | 2008-04-24 | Erimos Pharmaceuticals Llc | Formulations for Injection of Catecholic Butanes, Including Ndga Compounds, Into Animals |
US20060276423A1 (en) * | 2005-04-18 | 2006-12-07 | Rachel Altura | Survivin-directed RNA interference-compositions and methods |
US8367126B2 (en) | 2005-09-27 | 2013-02-05 | University Of Kentucky Research Foundation | Berry preparations and extracts |
WO2007038421A2 (en) * | 2005-09-27 | 2007-04-05 | University Of Kentucky Research Foundation | Berry preparations and extracts |
WO2007101111A2 (en) * | 2006-02-23 | 2007-09-07 | Erimos Pharmaceuticals Llc | Methods of treating influenza viral infections |
CA2661274A1 (en) * | 2006-08-29 | 2008-03-06 | University Of Kentucky Research Foundation | Compositions and methods for oral cancer chemoprevention using berry preparations and extracts |
US9067875B2 (en) | 2006-10-02 | 2015-06-30 | Erimos Pharmaceuticals Llc | Tetra-substituted NDGA derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use |
US8178527B2 (en) * | 2006-10-02 | 2012-05-15 | Erimos Pharmaceuticals Llc | Tetra-substituted NDGA derivatives via ether bonds and carbamate bonds and their synthesis and pharmaceutical use |
US20100093872A1 (en) * | 2008-10-15 | 2010-04-15 | Erimos Pharmaceuticals Llc | Stable aqueous formulations of water insoluble or poorly soluble drugs |
CN101690829B (en) * | 2009-08-31 | 2013-09-18 | 中国科学院上海硅酸盐研究所 | Method for preparing re-cellularized biological valve material |
WO2011030329A1 (en) | 2009-09-10 | 2011-03-17 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method of treating tumors |
CA2825894C (en) | 2011-02-02 | 2021-11-30 | Amgen Inc. | Prognosis of cancer using a circulating biomarker |
US10342767B2 (en) | 2011-04-21 | 2019-07-09 | Children's Hospital Medical Center | Therapy for kinase-dependent malignancies |
CA2832860A1 (en) * | 2011-04-21 | 2012-10-26 | Children's Hospital Medical Center | Therapy for leukemia |
AU2012335541B2 (en) | 2011-11-11 | 2017-07-06 | Duke University | Combination drug therapy for the treatment of solid tumors |
US8980259B2 (en) | 2012-07-20 | 2015-03-17 | Novartis Ag | Combination therapy |
WO2015013581A1 (en) | 2013-07-26 | 2015-01-29 | Update Pharma Inc. | Combinatorial methods to improve the therapeutic benefit of bisantrene |
WO2016209921A1 (en) | 2015-06-22 | 2016-12-29 | Janssen Biotech, Inc. | Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors |
WO2017129763A1 (en) | 2016-01-28 | 2017-08-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of signet ring cell gastric cancer |
MX2017002227A (en) | 2017-02-17 | 2018-08-16 | Promotora Tecnica Ind S A De C V | Composition based on nordihydroguaiaretic acid. |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5276060A (en) * | 1979-06-19 | 1994-01-04 | Block/Chemex, G.P. | Methods of treating tumors with compositions of catecholic butanes |
US5008294A (en) | 1985-02-11 | 1991-04-16 | Chemex Pharmaceuticals, Inc. | Methods of treating tumors with compositions of catecholic butanes |
DE3009542A1 (en) | 1980-03-13 | 1981-09-24 | Henkel KGaA, 4000 Düsseldorf | DESODORING COSMETIC COMPOSITIONS |
US4774229A (en) * | 1982-04-05 | 1988-09-27 | Chemex Pharmaceuticals, Inc. | Modification of plant extracts from zygophyllaceae and pharmaceutical use therefor |
US4708964A (en) * | 1984-02-09 | 1987-11-24 | Chemex Pharmaceuticals | Lipoxygenase inhibitors |
US4880637A (en) | 1985-02-11 | 1989-11-14 | Chemex Pharmaceuticals, Inc. | Compositions of catecholic butanes with zinc |
WO1988001509A1 (en) * | 1986-08-25 | 1988-03-10 | Chemex Pharmaceuticals, Inc. | Pharmacologically active compositions of catecholic butanes with zinc |
US5559149A (en) | 1990-01-29 | 1996-09-24 | Johnson & Johnson Consumer Products, Inc. | Skin care compositions containing retinoids |
US5646186A (en) | 1994-05-17 | 1997-07-08 | Johnson & Johnson Consumer Products, Inc. | Retinoid composition |
US5409690A (en) * | 1993-06-23 | 1995-04-25 | Chemex Pharmaceuticals, Inc. | Treatment of multidrug resistant diseases in cancer cell by potentiating with masoprocol |
US6365787B1 (en) | 1994-09-30 | 2002-04-02 | The Johns Hopkins University | Compounds for the suppression of HIV TAT transactivation |
US6071949A (en) * | 1995-03-14 | 2000-06-06 | The United States Of America As Represented By The Department Of Health And Human Services | Use of lipoxygenase inhibitors as anti-cancer therapeutic and intervention agents |
US5837252A (en) | 1996-07-01 | 1998-11-17 | Larreacorp, Ltd. | Nontoxic extract of Larrea tridentata and method of making same |
US5827898A (en) | 1996-10-07 | 1998-10-27 | Shaman Pharmaceuticals, Inc. | Use of bisphenolic compounds to treat type II diabetes |
WO1998022589A2 (en) * | 1996-11-20 | 1998-05-28 | Yale University | Survivin, a protein that inhibits cellular apoptosis, and its modulation |
US6077709A (en) * | 1998-09-29 | 2000-06-20 | Isis Pharmaceuticals Inc. | Antisense modulation of Survivin expression |
US6214874B1 (en) * | 1999-10-15 | 2001-04-10 | John Hopkins University | Treatment of HPV induced cancer using in situ application of two nordihydroguiaretic acid derivatives, tetramethyl NDGA M4N and tetraglycinal NDGA G4N |
US6608108B2 (en) * | 1999-10-15 | 2003-08-19 | Johns Hopkins University | Method for treatment of tumors using nordihydroguaiaretic acid derivatives |
-
2001
- 2001-05-09 US US09/851,425 patent/US6608108B2/en not_active Expired - Lifetime
-
2002
- 2002-05-08 JP JP2002586930A patent/JP2004534025A/en active Pending
- 2002-05-08 CA CA002447045A patent/CA2447045A1/en not_active Withdrawn
- 2002-05-08 AU AU2002311890A patent/AU2002311890C1/en not_active Ceased
- 2002-05-08 EP EP02739227.3A patent/EP1392293B1/en not_active Expired - Lifetime
- 2002-05-08 WO PCT/US2002/014374 patent/WO2002089795A1/en active Application Filing
- 2002-05-08 SG SG200507965-2A patent/SG169224A1/en unknown
- 2002-05-08 CN CN028138627A patent/CN1525857B/en not_active Expired - Lifetime
- 2002-10-15 US US10/270,313 patent/US6777444B2/en not_active Expired - Lifetime
-
2003
- 2003-12-16 US US10/735,910 patent/US8318815B2/en not_active Expired - Lifetime
-
2009
- 2009-07-29 JP JP2009177106A patent/JP2009242438A/en active Pending
Non-Patent Citations (5)
Title |
---|
AMBROSINI GRAZIA ET AL: "A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma", 1997, NATURE MEDICINE, VOL. 3, NR. 8, PAGE(S) 917-921 ISSN: 1078-8956 * |
CRIAGO ET AL: "Inhibition of human papillomavirus type 16 gene expression by nordihydroguaiaretic acid plant lignan derivatives", ANTIVIRAL RESEARCH, vol. 47, 2000, pages 19-28, XP008068872, * |
J.D.HELLER ET ALL.: "Tetra-O-methyl nordihydroguaiaretic acid induces G2 arrest in mammalian cells and exhibits tumoricidal activity in vivo" CANCER RESEARCH, vol. 61, 15 July 2001 (2001-07-15), pages 5499-5504, XP002322391 * |
JOSHUA D. LAMBERT ET ALL.: "Tetra-O-Methylnordihydroguaiaretic acid inhibits melanoma in vivo" CANCER LETTERS, vol. 171, 28 August 2001 (2001-08-28), pages 47-56, XP002322390 * |
See also references of WO02089795A1 * |
Also Published As
Publication number | Publication date |
---|---|
US20040127562A1 (en) | 2004-07-01 |
CN1525857A (en) | 2004-09-01 |
US20030171416A1 (en) | 2003-09-11 |
WO2002089795A1 (en) | 2002-11-14 |
AU2002311890B2 (en) | 2007-07-26 |
US8318815B2 (en) | 2012-11-27 |
CN1525857B (en) | 2013-06-12 |
CA2447045A1 (en) | 2002-11-14 |
US20020065310A1 (en) | 2002-05-30 |
SG169224A1 (en) | 2011-03-30 |
AU2002311890C1 (en) | 2008-05-15 |
US6608108B2 (en) | 2003-08-19 |
JP2004534025A (en) | 2004-11-11 |
EP1392293A4 (en) | 2005-05-25 |
JP2009242438A (en) | 2009-10-22 |
EP1392293B1 (en) | 2016-10-26 |
US6777444B2 (en) | 2004-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6608108B2 (en) | Method for treatment of tumors using nordihydroguaiaretic acid derivatives | |
AU783015C (en) | Nordihydroguaiaretic derivatives for use in treatment of tumors | |
AU2002311890A1 (en) | Method for treatment of tumors using nordihydroguaiaretic acid derivatives | |
TWI622406B (en) | Uses of compounds and mixtures from antrodia cinnamomea mycelia | |
Zhao et al. | Inhibition of MEK5/ERK5 signaling overcomes acquired resistance to the third generation EGFR inhibitor, osimertinib, via enhancing Bim-dependent apoptosis | |
Jin et al. | Acacetin inhibits RANKL-induced osteoclastogenesis and LPS-induced bone loss by modulating NFATc1 transcription | |
WO2002030425A1 (en) | Preventives and remedies for complications of diabetes | |
US6441009B1 (en) | Agent and method of preventing and treating heavy metal exposure and toxicity | |
MXPA02003799A (en) | Nordihydroguaiaretic derivatives for use in treatment of tumors | |
RU2440128C1 (en) | Method of complex pathogenetic therapy of acute forms of viral hepatitis b and mixed hepatites (b+c, b+d, b+c+d) | |
Wei et al. | Celastrol alleviates secondary brain injury following intracerebral haemorrhage by inhibiting neuronal ferroptosis and blocking blood-brain barrier disruption | |
US6238659B1 (en) | Agent for treating papilloma virus-positive malignant and premalignant lesions | |
EA039331B1 (en) | Composition for the treatment of human papilloma virus cutaneous infections |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20031203 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1062635 Country of ref document: HK |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20050412 |
|
17Q | First examination report despatched |
Effective date: 20060920 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Ref document number: 60248438 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: A61K0031417000 Ipc: A61P0035020000 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/075 20060101ALI20160415BHEP Ipc: A61K 31/405 20060101ALI20160415BHEP Ipc: A61P 35/02 20060101AFI20160415BHEP Ipc: A61K 31/198 20060101ALI20160415BHEP Ipc: A61K 31/417 20060101ALI20160415BHEP Ipc: A61K 31/225 20060101ALI20160415BHEP Ipc: A61K 31/401 20060101ALI20160415BHEP |
|
INTG | Intention to grant announced |
Effective date: 20160506 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R081 Ref document number: 60248438 Country of ref document: DE Owner name: THE JOHNS HOPKINS UNIVERSITY, BALTIMORE, US Free format text: FORMER OWNER: THE JOHNS HOPKINS UNIVERSITY, BALTIMORE, MD., US |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 839597 Country of ref document: AT Kind code of ref document: T Effective date: 20161115 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 60248438 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20161026 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 839597 Country of ref document: AT Kind code of ref document: T Effective date: 20161026 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161026 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170127 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 16 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161026 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161026 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161026 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161026 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161026 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20170227 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R082 Ref document number: 60248438 Country of ref document: DE Representative=s name: LEINWEBER & ZIMMERMANN, DE Ref country code: DE Ref legal event code: R082 Ref document number: 60248438 Country of ref document: DE Representative=s name: LEINWEBER & ZIMMERMANN PATENTANWALTS-PARTG MBB, DE Ref country code: DE Ref legal event code: R081 Ref document number: 60248438 Country of ref document: DE Owner name: THE JOHNS HOPKINS UNIVERSITY, BALTIMORE, US Free format text: FORMER OWNER: JOHNS HOPKINS UNIVERSITY, BALTIMORE, MD., US |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: S117 Free format text: REQUEST FILED; REQUEST FOR CORRECTION UNDER SECTION 117 FILED ON 26 MAY 2017 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 60248438 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161026 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161026 Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170531 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20170727 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: RM Effective date: 20171208 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1062635 Country of ref document: HK |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161026 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170531 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170531 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170508 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170508 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 17 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20161026 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161026 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20210527 Year of fee payment: 20 Ref country code: FR Payment date: 20210525 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20210527 Year of fee payment: 20 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R071 Ref document number: 60248438 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: PE20 Expiry date: 20220507 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20220507 |